← Back to Home

Skyrizi induction regimen for Crohn’s disease approved in the U.S., allowing treatment to begin at home

The new regimen extends home injections to the start of treatment, giving patients another option for fitting treatment into daily life. The supporting trial showed that subcutaneous injections outperformed placebo, but the findings do not yet allow comparisons of efficacy with intravenous infusions or other drugs.

By SURL BioNews

For patients with Crohn’s disease who need long-term control of intestinal inflammation, how treatment fits into daily life is an important part of medication use. On October 23, 2026, AbbVie announced that the U.S. Food and Drug Administration (FDA) had approved a subcutaneous induction regimen for Skyrizi (risankizumab-rzaa), allowing adults with moderately to severely active Crohn’s disease to begin treatment at home using an on-body injector. The approval extends home administration, previously used for maintenance treatment, to the initial treatment phase.

Induction treatment aims to control disease activity early in the treatment course. The new regimen consists of 720 mg administered subcutaneously at weeks 0, 2, 4, and 8. The existing intravenous infusion regimen remains an option, with 600 mg administered at weeks 0, 4, and 8. Both routes are followed by maintenance treatment beginning at week 12, administered through an on-body injector every eight weeks. This approval adds flexibility to how treatment begins.

Skyrizi is an antibody drug that targets interleukin-23 (IL-23), binding to its p19 subunit to inhibit associated inflammatory signaling. The approval was supported by the phase 3 AFFIRM trial. According to HCPLive, the randomized, double-blind study assigned 274 adults to receive either the subcutaneous drug or placebo. Approximately 65% of participants had experienced an inadequate response, loss of response, or intolerance to advanced therapies, indicating that the study included many patients who had already experienced treatment setbacks.

At week 12, 56% of patients in the drug group achieved clinical remission, compared with 30% in the placebo group. Endoscopic response rates were 43% and 15%, respectively, with both co-primary endpoints reaching statistical significance. Clinical remission was defined as a Crohn’s Disease Activity Index score below 150, while endoscopic response assessed improvement in intestinal lesions. Rates for the more stringent secondary endpoint of endoscopic remission were 26% and 11%, respectively. These results support the efficacy of subcutaneous induction in terms of both disease activity and intestinal examination findings.

In the subgroup without prior advanced therapy failure, the clinical remission rate was 74%, compared with 27% in the placebo group. However, this subgroup included only 65 participants receiving the drug and 33 receiving placebo, so the findings require cautious interpretation. “No prior treatment failure” also does not necessarily mean no prior exposure to advanced therapies. The statistical significance of the overall trial cannot be directly applied to every subgroup, much less support a conclusion of superiority over other drugs.

Regarding safety, AbbVie said the subcutaneous induction regimen was generally consistent with Skyrizi’s established safety profile, with no new safety risks identified. This conclusion comes from the trial sponsor’s summary; existing warnings about infections, severe allergic reactions, and hepatotoxicity still need to be considered. The FDA also updated labeling across indications to allow physicians to use clinical judgment in deciding whether a tuberculosis evaluation is needed before treatment. Liver function monitoring requirements for patients with Crohn’s disease remain in place.

The most immediate significance of this approval is that patients and physicians can reconsider where and how treatment begins. Whether home induction can improve long-term treatment persistence will require further data. Pharmaceutical Executive noted that the announcement did not provide results from AFFIRM’s extended follow-up period, nor evidence directly comparing subcutaneous and intravenous induction regimens or comparing the regimen with other drugs. The week 12 efficacy results do not yet provide a complete picture of long-term disease control.

References

  1. AbbVie
  2. HCPLive
  3. Pharmaceutical Executive